Why MTAP deletions matter
The presence of MTAP deletions puts patients at a disadvantage.1,2
Outcomes are often worse for patients with MTAP deleted tumors.1,2
On front-line standard-of-care therapies, patients with MTAP deleted NSCLC have numerically shorter OS than patients with MTAP wild-type NSCLC.1
Adapted from Reck et al. 2026 |
|
| * | Data are from the TEMPUS database. |
For patients with PDAC, the chance of survival remains poor for those with MTAP deleted tumors2
Adapted from Tatman et al. 2026 |
|
| † | Indexed at first treatment; median follow-up, 14.7 months (range, 0.4–71.6). ‡Adjusted for age, sex, and treatment type of first regimen, as well as for delayed entry. §Due to delayed entry, patients entered the cohort at different times relative to study start, contributing to risk only from their entry time. |
MTAP deletion is an unmet need among precision medicine approaches. Patients with this distinct molecular subset experience suboptimal outcomes on existing therapies.2,3||
Make MTAP testing routine.
Patients with MTAP deletions deserve continued research in this area.
|| |
Particularly in immunologically “cold” tumor environments.3 |
1L=first line; CI=confidence interval; del=deletion; I-O=immuno-oncology; MTAP=methylthioadenosine phosphorylase; NSCLC=non-small cell lung cancer; OS=overall survival; PDAC=pancreatic ductal adenocarcinoma; wt=wild type. |
|
References: 1. Reck M, Tatman M, Liu C, et al. Clinical, genomic, and tumor microenvironment characterization of MTAP-deletion in advanced/metastatic non-small cell lung cancer. Poster presentation at ELCC 2026. Poster 63P. 2. Tatman M, Brennan DH, Liu C, et al. Genomic characteristics, clinical profiling, and outcomes of advanced pancreatic ductal adenocarcinoma with MTAP-deletion: analyses from a multimodal real-world dataset. Poster presentation at ASCO-GI 2026. Poster H4. 3. Han G, Yang G, Hao D, et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021. doi:10.1038/s41467-021-25894-9. |
Explore ongoing BMS MTAP trials worldwide
